Search

BioMarin Pharmaceutical Inc

Cerrado

SectorSanidad

66.34 0.21

Resumen

Variación precio

24h

Actual

Mínimo

65.31

Máximo

66.63

Métricas clave

By Trading Economics

Ingresos

-61M

45M

Ventas

224M

990M

P/B

Media del Sector

176.297

56.659

BPA

0.9

Margen de beneficios

4.523

Empleados

3,221

EBITDA

50M

222M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+39.86% upside

Dividendos

By Acuity

Próximas Ganancias

26 oct 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1B

13B

Apertura anterior

66.13

Cierre anterior

66.34

Noticias sobre sentimiento de mercado

By Acuity

28%

72%

74 / 339 Clasificación en Healthcare

BioMarin Pharmaceutical Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 sept 2026, 20:07 UTC

BioMarin Pharmaceutical Inc shares are higher in Friday's session, despite earlier pullbacks. No specific news was identified to explain the movement.

3 sept 2026, 19:46 UTC

News
Social Media

BioMarin Pharmaceutical completes a $275 million acquisition, impacting its strategic positioning. Shares are lower during Thursday's session amid broader biotech M&A activity.

2 sept 2026, 23:01 UTC

BioMarin Pharmaceutical Inc. shares declined in after-market trading, reversing earlier gains amid broader market concerns tied to U.S.-Iran tensions and rising oil prices.

1 sept 2026, 19:46 UTC

News

BioMarin Pharmaceutical completed its acquisition of Alesta Therapeutics today. Despite this, shares are lower amid integration concerns and ongoing clinical evaluations.

31 ago 2026, 21:01 UTC

BioMarin Pharmaceutical shares are lower in after-market trading amid cautious market sentiment influenced by hawkish comments from Fed Chair Kevin Warsh on inflation.

24 ago 2026, 19:26 UTC

Social Media

BioMarin Pharmaceutical announced its $275 million acquisition of Alesta Therapeutics. Shares are trading lower amid ongoing market volatility and geopolitical tensions.

21 ago 2026, 19:16 UTC

Biomarin Pharmaceutical Inc shares are lower today, despite earlier gains. Broader market volatility linked to rising crude oil prices may be influencing sentiment.

20 ago 2026, 19:16 UTC

News
Social Media

BioMarin Pharmaceutical shares are lower despite BMO initiating coverage with an Outperform rating and a price target of $98.

19 ago 2026, 23:51 UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

18 ago 2026, 23:41 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, reflecting broader market declines amid profit-taking in technology and concerns over rising bond yields.

17 ago 2026, 19:16 UTC

News

BioMarin shares are lower despite price target increases from Barclays and Piper Sandler, reflecting ongoing downward performance trends in recent sessions.

14 ago 2026, 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from recent gains. Broader market sentiment is mixed amid a decline in U.S. retail sales.

13 ago 2026, 22:36 UTC

Biomarin Pharmaceutical shares are higher in after-market hours, reflecting broader market positivity following the S&P 500's record close and easing inflation concerns.

12 ago 2026, 23:01 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, with no specific news identified to explain the decline following five consecutive sessions of gains.

11 ago 2026, 19:56 UTC

Biomarin Pharmaceutical Inc shares are higher, continuing a recent upward trend. Market focus is on upcoming economic indicators, including the Consumer Price Index report.

10 ago 2026, 23:26 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading. Broader market sentiment remains cautious amid geopolitical tensions affecting investor confidence.

7 ago 2026, 23:16 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. The broader market declined following recent labor market data affecting Federal Reserve rate hike expectations.

6 ago 2026, 23:02 UTC

News

BioMarin Pharmaceutical reported second-quarter EPS of $1.20, surpassing estimates. Shares are trading higher in after-market hours following strong revenue growth and raised guidance.

5 ago 2026, 23:56 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours amid routine trading, with no specific news identified to explain the movement.

4 ago 2026, 19:46 UTC

Biomarin Pharmaceutical Inc shares are higher, supported by broader market strength amid a decline in crude oil prices, easing inflation concerns.

3 ago 2026, 23:31 UTC

News

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

31 jul 2026, 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today amid broader market declines, pressured by rising Treasury yields and increased crude oil prices.

30 jul 2026, 19:08 UTC

Biomarin Pharmaceutical Inc shares are lower today, reflecting a decline since Wednesday's close amid broader economic uncertainty from rising jobless claims and weak GDP growth.

29 jul 2026, 18:14 UTC

Biomarin Pharmaceutical Inc shares are lower today, with no specific news identified. Market sentiment remains mixed amid speculation on potential Federal Reserve rate hikes.

28 jul 2026, 18:02 UTC

Biomarin Pharmaceutical is trading higher, benefiting from a strong Biotechnology sub-sector trend. Shares reached a peak earlier in the session amid favorable market conditions.

27 jul 2026, 19:01 UTC

News

BioMarin Pharmaceutical announced a collaboration with the n-Lorem Foundation to develop a treatment for ReNU syndrome, boosting shares during Monday's session.

24 jul 2026, 15:46 UTC

Biomarin Pharmaceutical shares are higher today, reflecting a broader market rebound amid a significant decline in oil prices.

22 jul 2026, 23:31 UTC

Biomarin Pharmaceutical shares traded roughly flat in after-market hours amid rising crude oil prices and geopolitical tensions affecting market sentiment.

21 jul 2026, 15:36 UTC

Biomarin Pharmaceutical Inc shares are higher as the Nasdaq gains, supported by strong technology stocks. The stock trades above its 20-day moving average.

20 jul 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, remaining above their 20-day moving average amid broader market concerns over interest rates and economic growth.

Comparación entre iguales

Cambio de precio

BioMarin Pharmaceutical Inc previsión

Precio Objetivo

By TipRanks

39.86% repunte

Estimación a 12 Meses

Media 93.05 USD  39.86%

Máximo 124 USD

Mínimo 60 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioMarin Pharmaceutical Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

20 ratings

15

Comprar

5

Mantener

0

Vender

Sentimiento

By Acuity

74 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat